HPV Genotype 18: Infection, Diagnosis, and Treatment

HPV genotype 18 is the second most cancer-causing type of human papillomavirus after HPV 16, and it carries a distinctive risk profile that sets it apart from most other high-risk HPV strains. While HPV 16 dominates overall cervical cancer statistics, HPV 18 is disproportionately linked to adenocarcinoma, a form of cervical cancer that starts in glandular cells higher up in the cervical canal and is harder to catch on routine screening. That difference in where and how it attacks has practical consequences for how infections are diagnosed, monitored, and treated.

Why HPV 18 Gets Special Attention

More than 200 types of HPV exist, but only about a dozen are classified as high-risk for cancer. Among those, HPV 16 and 18 together cause the majority of cervical cancers worldwide. HPV 18 on its own accounts for roughly 12% of squamous cell carcinomas of the cervix and about 37% of cervical adenocarcinomas.¹ That second number is what makes HPV 18 stand out: adenocarcinomas are less common than squamous cell cancers overall, but HPV 18 is responsible for a strikingly large share of them. A separate worldwide analysis of cervical adenocarcinomas found that HPV 16, 18, and 45 together accounted for about 94% of HPV-positive adenocarcinoma tumors, with HPV 18 alone present in nearly 32% of cases.²

Adenocarcinomas tend to develop deeper in the cervical canal, where standard Pap smears are less effective at catching abnormal cells. This means HPV 18-driven cancers can grow silently for longer before detection. It also explains why screening guidelines in many countries now include specific genotyping for HPV 16 and 18: a positive result for either type triggers more aggressive follow-up than a positive result for other high-risk types.

How HPV 18 Drives Cells Toward Cancer

The reason HPV 18 is so dangerous comes down to two viral proteins, E6 and E7, which hijack the cell’s normal growth controls. The E6 protein targets a tumor suppressor called p53, which normally acts as a brake on cell division when DNA is damaged. High-risk HPV types like HPV 18 produce an E6 protein that marks p53 for destruction, effectively removing one of the cell’s key safety mechanisms.³ The E7 protein, meanwhile, disables another tumor suppressor called Rb, pushing cells to divide when they otherwise would not.

HPV 18’s E6 protein is particularly efficient at degrading p53. Research comparing how E6 breaks down p53 in different cell types has confirmed that this ability is a core feature of cancer-causing HPV strains.⁴ Interestingly, a shorter variant of the HPV 18 E6 protein, called E6*I, can actually block full-length E6 from degrading p53, restoring some of p53’s protective activity. This interaction has been documented at the molecular level, where E6*I physically binds to full-length E6 and interferes with its function.⁵ That splicing quirk has drawn attention from researchers working on potential therapeutic targets, though it hasn’t yet translated into a clinical tool.

Beyond disabling tumor suppressors, HPV 18 can destabilize the genome more directly when its DNA integrates into human chromosomes. Studies of HeLa cells, a cervical cancer cell line that carries HPV 18, found viral DNA integrated at four chromosomal sites, three of which sit near known cancer-related genes (MYC, ABL, and SIS) and close to fragile sites where chromosomes are prone to breaking.⁶ Separate work has shown that when HPV 18 inserts itself near the MYC gene, it creates a zone of increased DNA replication activity, with more replication starting points firing than normal and more of those replication forks stalling, a recipe for the kind of genomic chaos that drives cancer progression.⁷

How HPV 18 Evades the Immune System

One reason HPV 18 infections can persist long enough to cause precancer and cancer is that the virus actively interferes with the body’s immune defenses. The same E6 and E7 proteins that disarm tumor suppressors also suppress interferon signaling, which is one of the immune system’s primary antiviral alarm systems. By blunting interferon production and the cellular response to it, HPV 18 can maintain an infection for months or years without triggering an effective immune reaction.⁸

This immune evasion helps explain why HPV-related lesions can persist for extended periods even in otherwise healthy people. The virus essentially keeps its head down, replicating in cells that are on their way to being shed from the skin or mucosal surface, and damping down the immune signals that would normally flag infected cells for destruction.

Persistence and Clearance

Most HPV infections, including HPV 18 infections, clear on their own within one to two years. But “most” is not “all,” and the infections that persist are the ones that matter for cancer risk. In a Dutch cohort of young women, about 44% of HPV 18 infections were persistent while 56% cleared.⁹ Those numbers are worth pausing on: a coin-flip chance of persistence is notably high for a viral infection that has no approved antiviral treatment.

Among women treated for cervical dysplasia, clearance rates for HPV 18 also tell a mixed story. In one Ethiopian cohort followed after treatment, HPV 18 showed a persistence rate of about 56% at six months and roughly 44% at twelve months, meaning more than half of treated women still carried the virus half a year later, and almost half still had it a full year out.¹⁰ That rate was comparable to HPV 16 and some other high-risk types, which underscores why post-treatment surveillance for HPV 18 is considered important.

Screening and Diagnosis

The standard approach to cervical cancer screening has shifted over the past two decades from relying solely on Pap smears to incorporating molecular HPV testing. Modern screening typically involves testing a cervical sample for high-risk HPV DNA. When the test comes back positive, some assays can identify the specific genotype, and guidelines in many countries recommend immediate further workup (usually colposcopy) when HPV 16 or 18 is detected, rather than taking a wait-and-see approach.

This genotype-specific triage reflects HPV 18’s unusual risk profile. Because HPV 18 preferentially causes adenocarcinoma, which develops in glandular tissue that is harder to visualize on colposcopy and easier to miss on Pap smears, knowing that a patient carries HPV 18 raises the urgency of follow-up. When HPV 16, 18, or 45 is detected alongside atypical glandular cells on cytology, the absolute risk of finding adenocarcinoma or its precursor (adenocarcinoma in situ) has been reported at about 12%, with an extraordinarily elevated odds ratio compared to women with other high-risk HPV types and normal cytology.¹¹

Adding HPV 16/18 genotype triage to screening programs has also been evaluated on economic terms. An analysis of U.S. screening strategies found that genotype triage was a cost-effective addition when combined with HPV and liquid-based cytology co-screening.¹² The logic is straightforward: the cost of performing a genotyping reflex test is modest compared to the cost of missing an adenocarcinoma that is growing silently in the cervical canal.

DNA Testing vs. mRNA Testing

Not all HPV molecular tests work the same way. DNA-based tests detect whether the virus’s genetic material is present, while mRNA-based tests look for active expression of the E6 and E7 cancer-driving genes. The difference matters because a woman can carry HPV DNA without the virus actively producing the proteins that lead to cancer. In a prospective Iranian cohort, the positivity rate for HPV by DNA testing was 18%, compared to about 11% by mRNA testing. The DNA test was highly sensitive (catching about 95% of truly active infections as defined by the mRNA test) but had lower specificity, meaning it flagged more women who were not actually at immediate risk.¹³ Comparisons within women who had abnormal Pap smears showed high agreement between DNA-based and mRNA-based approaches when cytology abnormalities were more severe, but the mRNA test flagged fewer women at the lower end of the abnormality spectrum.¹⁴

p16/Ki67 Dual Staining as a Triage Tool

Another approach gaining traction is p16/Ki67 dual staining, a lab test that looks at two cellular markers to determine whether HPV is actually driving abnormal cell growth. In women with low-grade cervical smears, dual staining had higher specificity and accuracy than HPV 16/18 genotyping alone for detecting underlying high-grade lesions, although the two tests had comparable sensitivity.¹⁵ One quirk of this approach is that p16/Ki67 positivity varies by genotype. In one study using the Onclarity genotyping platform, HPV 18-positive samples had a dual-staining positivity rate of only 25%, compared to 100% for HPV 33/58-positive samples.¹⁶ This suggests that relying on dual staining alone could miss a meaningful proportion of HPV 18-driven disease, reinforcing the value of genotype-specific triage.

Prevention Through Vaccination

All currently available HPV vaccines cover HPV 18. The nonavalent vaccine (Gardasil 9), which is the primary vaccine used in most countries today, protects against nine HPV types including the two highest-risk strains (16 and 18), five additional high-risk types (31, 33, 45, 52, and 58), and two low-risk types (6 and 11) that cause genital warts.¹⁷ Real-world data confirm that vaccinated women show notably lower rates of HPV 6, 11, 16, and 18 infection compared to unvaccinated women.¹⁸

HPV 18 belongs to a family of related genotypes called the alpha-7 group, which also includes HPV 39, 45, 59, 68, and 70. This evolutionary kinship means vaccines targeting HPV 18 can offer some cross-protection against its close relatives. Results from the Costa Rica Vaccine Trial found that the bivalent HPV vaccine (which targets HPV 16 and 18) provided partial cross-protection against HPV 31, 33, and 45 infection.¹⁹ A population-level analysis over 11 years found that the prevalence of HPV types genetically related to HPV 18 showed a non-significant decrease of about 14% after vaccine introduction, with no evidence of type replacement (where non-vaccine types become more common to fill the ecological niche).²⁰

Experimental work has pushed the cross-protection idea further. A chimeric vaccine particle built from HPV 18 and HPV 45 components induced antibodies that neutralized HPV 18, 39, 45, and 68 in laboratory tests, though not HPV 59 or the distantly related HPV 16.²¹ This kind of work remains preclinical but illustrates the potential for broader alpha-7 coverage with a single vaccine component.

Treatment of HPV 18-Related Precancers

There is no antiviral drug that targets HPV 18 directly. Treatment focuses on removing the abnormal tissue the virus causes. For precancerous cervical lesions, the two main surgical options are loop electrosurgical excision procedure (LEEP) and cold-knife conization. Both remove a cone-shaped piece of cervical tissue that contains the abnormal cells.

For adenocarcinoma in situ (AIS), the immediate precursor to invasive adenocarcinoma that HPV 18 frequently drives, either procedure appears effective. A systematic review and meta-analysis comparing LEEP and cold-knife conization for AIS found comparable rates of residual disease and recurrence, but LEEP was associated with fewer obstetric complications, making it a preferred option for women who want to preserve fertility.²² Traditional guidelines have recommended hysterectomy after treatment of AIS, but newer evidence challenges that approach. A study following women treated by conization alone found that routine hysterectomy as part of the AIS treatment algorithm was unnecessary, provided serial surveillance was maintained.²³

For invasive cervical cancer, treatment follows the standard oncology playbook based on stage: surgery for early-stage disease, chemoradiation for locally advanced disease. The HPV genotype does not typically change the treatment protocol for invasive cancer, though knowing that a cancer is HPV 18-driven can inform prognosis and surveillance decisions.

Emerging Therapeutic Vaccines

Unlike preventive vaccines that stop infection from taking hold, therapeutic vaccines aim to treat existing HPV-driven disease by training the immune system to recognize and attack cells already expressing HPV proteins. This is an active area of research, and several approaches are in preclinical or early clinical development for HPV 18.

One promising direction uses mRNA technology. Researchers have developed mRNA-based therapeutic vaccines encapsulated in lipid nanoparticles that encode mutated versions of the HPV 16 and HPV 18 E6 and E7 proteins, paired with an optimized immune-stimulating adjuvant. In mouse models, these vaccines promoted tumor-specific immune responses and worked synergistically with anti-PD-1 checkpoint blockade to drive tumor regression.²⁴ This is still preclinical work, but the combination of mRNA vaccine technology with immune checkpoint inhibitors reflects a broader trend in cancer immunotherapy.

A significant challenge for therapeutic vaccines targeting HPV 18 is the variability of immune responses across individuals. Work identifying which fragments of HPV 18’s E6 and E7 proteins are recognized by the immune system found that a therapeutic DNA vaccine targeting HPV 18 E7 generated strong immune responses in mice carrying certain human immune system variants (HLA-A2 and HLA-A11) but failed to generate meaningful responses in mice with other variants.²⁵ This suggests that therapeutic vaccines may need to be tailored to different populations based on their immune system genetics, a complexity that does not exist for preventive vaccines.

Methylation-Based Biomarkers for Early Detection

One of the frontiers in HPV 18-related diagnostics is DNA methylation testing. As HPV infections progress toward cancer, characteristic chemical modifications (methyl groups) accumulate on both human and viral DNA. These methylation patterns can serve as biomarkers that flag which infections are on a dangerous trajectory long before tissue changes become visible.

A study developing a combined human-and-HPV DNA methylation score found that it could detect cervical adenocarcinoma and its precursor (AIS) with about 74% sensitivity and 89% specificity from self-collected cervicovaginal samples.²⁶ That performance is particularly relevant for HPV 18 because of its strong association with adenocarcinoma, which is the subtype most likely to be missed by conventional cytology. Other research has identified specific gene promoters whose methylation status distinguishes cervical cancer from normal tissue and high-grade precancerous lesions, suggesting a cascade of methylation events during cancer development that could be intercepted with the right test.²⁷

The combination of methylation testing with HPV genotyping is where this technology gets especially interesting. A methylation marker system called S5 has shown the ability to combine the predictive power of methylation with HPV genotyping, identifying high-risk HPV-positive women who are most likely to develop high-grade disease or invasive cancer in the future.²⁸ For HPV 18-positive women in particular, this kind of risk stratification could help solve one of the genotype’s central clinical challenges: distinguishing the infections that will clear from the ones heading toward adenocarcinoma, without resorting to invasive procedures on every positive patient.

HPV 18 Beyond the Cervix

Although cervical cancer is the disease most closely associated with HPV 18, this genotype is not limited to the cervix. HPV-related cancers also occur in the oropharynx (back of the throat), anus, vagina, vulva, and penis.¹⁷ HPV 16 dominates in oropharyngeal and anal cancers to a greater degree than in cervical cancer, but HPV 18 contributes to all of these sites to varying extents.

Geographic and genetic variation within HPV 18 itself also complicates the picture. Different sublineages of HPV 18 circulate in different populations, and research has found that these variants can differ in their cancer risk. Understanding the distribution of HPV 18 genetic diversity across populations has implications for designing diagnostic tests that do not miss regional variants and for ensuring vaccines remain effective against the strains circulating in a given area.²⁹ This is one reason global surveillance of HPV genotypes remains important even as vaccination programs expand: the virus evolves, populations differ, and a one-size-fits-all approach to screening and prevention has limits.